Related Experiment Videos
Acute myocardial infarction associated with prostaglandin E2
W J Meyer1, S L Benton, T J Hoon
1Division of Maternal-Fetal Medicine, University of Illinois, Chicago 60612.
American Journal of Obstetrics and Gynecology
|August 1, 1991
Summary
Prostaglandin E2 is generally safe for second-trimester pregnancy termination. However, this case highlights a rare risk of acute myocardial infarction in patients with pre-existing severe hypertension and kidney disease.
Area of Science:
- Obstetrics and Gynecology
- Cardiology
- Nephrology
Background:
- Second-trimester pregnancy termination commonly utilizes Prostaglandin E2.
- Serious maternal side effects are infrequent with Prostaglandin E2 use.
- Chronic glomerulosclerosis and severe hypertension are significant pre-existing conditions.
Observation:
- A case of acute myocardial infarction occurred during therapeutic pregnancy termination.
- The patient had a history of chronic glomerulosclerosis and severe hypertension.
- Prostaglandin E2 was the agent used for pregnancy termination.
Findings:
- This report details a rare instance of acute myocardial infarction.
- The infarction complicated a second-trimester pregnancy termination procedure.
- The patient's comorbidities likely contributed to the adverse event.
Implications:
- Healthcare providers should exercise caution when using Prostaglandin E2 in patients with severe hypertension and renal disease.
- This case underscores the importance of thorough patient evaluation for cardiovascular risk factors.
- Further research may be warranted to elucidate the specific mechanisms linking Prostaglandin E2 to myocardial infarction in high-risk populations.